鑫網易商(01039.HK):一買家終止認購附屬股權
鑫網易商(01039.HK)公布,有關於視作出售於一間附屬公司「分海」的股權的事宜,除北京信中利投資的認購事項外,餘下兩名其他投資者的認購事項已於2019年3月完成,集團已收到該認購事項所得款項總額2億元人民幣。
目前北京信中利投資的認購協議中的先決條件尚未完全達成或獲豁免。因此,信中利投資認購協議應立即自動終止。信中利投資認購協議終止後,PCL和北京信中利投資應解除其根據信中利投資認購協議所承擔的各自義務。
董事會認為,終止信中利投資認購協議不會對集團的業務營運或財務狀況或公司及其股東的整體利益造成任何重大不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.